Q4 results topped Wall Street expectations. Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars.
Eli Lilly's tirzepatide, branded as Zepbound, continues to dominate the weight-loss market as Novo Nordisk's CagriSema fails to outperform it in recent trials. This led to a 4% stock increase for Lilly while Novo's market value plummeted.
Du måste vara medlem för att kunna kommentera
Det är enkelt att registrera ett nytt konto
Har du redan ett konto? Logga in här